|Company name||Akers Biosciences, Inc.|
|Class period||5/15/2017 – 06/05/2018|
|Lead plaintiff deadline||August 13, 2018|
|Court||District of New Jersey|
NEW YORK, June 14, 2018 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Akers Biosciences, Inc. (NASDAQ: AKER) securities between May 15, 2017 and June 5, 2018 (the “Class Period”). Investors have until August 13, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that (1) Akers was improperly recognizing revenue for the fiscal year ended December 31, 2017; (2) Akers downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses; and (3) as a result, defendants’ statements about Akers’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The complaint claims that when the truth was revealed to the market, investors suffered damages.
If you purchased Akers Biosciences securities during the Class Period or continue to hold shares purchased before the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.